From March 21 to 23, 2026, the 23rd China International Exhibition for Laboratory Medicine and Blood Transfusion Instruments & Reagents (CACLP 2026) opened in grand style at the Xiamen International Expo Center.
As a long-time exhibitor, Xinke Medical answered the call once again. This time, the company brought multiple series of innovative products to the show, presenting a comprehensive picture of Xinke's R&D strength and industrialization capabilities in the field of IVD reagents.
Focused on Product Innovation to Advance Clinical Testing
During the exhibition, Xinke Medical launched a number of new products, continuously refining its product portfolio around the needs of clinical testing.
Among them, the CRP reagents made their official debut at this exhibition. Compatible with Mindray hematology analyzers, they enable combined blood cell analysis and CRP testing, closing the loop on integrated CBC + CRP testing and delivering strong stability and accuracy to fully support rapid clinical diagnosis.
At the same time, the company unveiled its new series of Immunoassay System Substrate Solutions, which achieve further improvements in luminescence efficiency and signal stability. Offering more stable and reliable support for chemiluminescence immunoassay testing, they are widely compatible with chemiluminescence immunoassay analyzers from all major brands.
Consolidating the Industrial Foundation, Refining the Product Portfolio
As an enterprise long devoted to the IVD segment, Xinke Medical has built a product system covering a wide range of application scenarios, including hematology analyzer reagents plus CRP reagents, biochemistry analyzer cleaning solutions, buffer, cleaning and substrate solutions for chemiluminescence immunoassay analyzers, reagents for urine / urine formed elements analyzers, and cleaning solutions for coagulation and hemorheology analyzers.
Relying on a well-developed R&D system and large-scale production capacity, the company keeps advancing product standardization and its quality control system, providing stable and reliable product support for clinical testing.
Deepening Exchange and Cooperation, Expanding the International Market
During the exhibition, the Xinke Medical booth attracted professional customers from Asia, Europe, Latin America, the Middle East and other countries and regions. The two sides held in-depth discussions on product performance, compatibility and cooperation models.
Through this exhibition, the company further strengthened its ties with partners at home and abroad, laying a solid foundation for its future expansion and cooperation in international markets.
CACLP 2026 — Innovation-Driven, Powering the Industry's High-Quality Development
As the IVD industry keeps evolving, product performance and technological innovation have become important drivers of industry progress. Xinke Medical stated that it will continue to increase its investment in R&D, optimize its product structure and improve service capabilities, steadily advancing toward high-quality development.
CACLP 2026 provided a high-level platform for exchange and cooperation across the industry. Xinke Medical will take this opportunity to deepen technological innovation and international cooperation, contributing to the development of laboratory medicine around the world.
Previous: Set Sail with Resolve, Gallop into a New Journey | A Recap of Xinke Medical's 2026 Horse-Year New Year Banquet
Next: State Council Sets the Direction: Tiered Diagnosis and Treatment Accelerates, Opening a Golden New Track for IVD in County-Level Markets